NO-releasing compounds

Mesoionic oxatriazolium-5-amenates 83 exhibit the whole range of biological properties typical of NO-releasing compounds that stimulate soluble guanylate cyclase namely antihypertensive activity in animals following the relaxation of the vascular... 

SIN-1 3-morpholinosydnonimine (a NO-releasing compound which is a metabolite of the vasodilator molsidomine SNP single nucleotide polymorphism SPE solid phase extraction ss single stranded SV sinusoidal voltammetry SVR surface -to-volume ratio TAE buffer Tris/acetate/EDTA buffer TAMRA 5-carboxytetramethylrhodamine... 

Lang DR, Davies JA, Lopes LGF, et al. A controlled NO-releasing compound synthesis, molecular structure, spectroscopy, electrochemistry, and chemical reactivity of R,R,5 )5 -fra s-[RuCl(NO)(cyclam)]5+ (1,4,8,11-tetraazacyclotetradecane). Inorg Chem. 2000 39 2294. 

GEA3162 and GEA3175 inhibited mononuclear cell proliferation dose-dependently and more potently than SNAP [61]. GEA3162 and GEA3175 also inhibited proliferative responses in human lymphocytes in a cGMP-independent manner and may have an immunosuppressant action [62]. Thus, NO-releasing compounds have immunosuppressive actions which offer therapeutic possibilities. 

This review has attempted to highlight the bio active mesoionic compounds and stimulate further development in this field. Mesoionic compounds are still considered as exotic structures even within the field of heterocyclic chemistry. Much attention has been directed toward the syd-nones (2), sydnonimines (3), l,2,3,4-oxatriazolium-5-aminates (9), and 1,3,4-thiadiazolium-2-aminates (7). In particular, their properties as NO-releasing compounds have been of interest. 

Marion Cottier and collaborators summarized in their chapter a set of observations that lead to the definition of NO as radiosensitizer molecule in bacteria and mammalian tumor cells. The effect of NO in the sensitization of tumor cell to radiotherapy has been demonstrated in preclinical and clinical studies. These effects can be either direct, by the cellular induction or generation of NO by the target tissue (NOS-mediated induction or activation) as revealed by Peter Siesjo in his chapter, or indirect by the use of NO-releasing compounds such as NO donors extensively discussed in these chapters. 

Several studies support the sensitizing role of NO to chemotherapy. As delineated by Marion Cortier and collaborators in their chapter, there are multiple evidences supporting the anti-tumor effect of cancer chemotherapeutic agents that are enhanced by the use of NO-releasing compounds. They examined this premise from two perspectives first, from the experimental point of view (preclinical) and the use of clean NO donors such as DETA/NO, DEA/NO, PAPA/NO and the modification of sensitivity of different cancer cells to chemotherapeutic drugs such as cisplatin, doxorubicin, melphalan second, the use of dirty NO donors but with... 

Timibull, C., Marcarino, R, Sheldrake, T., Lazzarato, L., Cena, C., Fruttero, R., Gasco, A., Fox, S., Megson, I., and Rossi, A. (2008). A novel hybrid aspirin-No-releasing compound inhibits Tnf-a relea.se from Lps-activated human monocytes and macrophages. J. Inflamm. 5,12. 

---